These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16459989)

  • 1. Neurofibromatosis-associated nerve sheath tumors. Case report and review of the literature.
    Murovic JA; Kim DH; Kline DG
    Neurosurg Focus; 2006 Jan; 20(1):E1. PubMed ID: 16459989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Seizures in neurofibromatosis. What is the risk?].
    Drouet A
    Rev Neurol (Paris); 2011 Dec; 167(12):886-96. PubMed ID: 22041820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polyneuropathy associated with neurofibromatosis].
    Drouet A; Créange A
    Rev Neurol (Paris); 2005 Mar; 161(3):275-83. PubMed ID: 15800448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Available Therapies for Patients with Neurofibromatosis-Related Nervous System Tumors.
    Strowd RE
    Curr Treat Options Oncol; 2020 Aug; 21(10):81. PubMed ID: 32767156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and genetic testing outcome of suspected hereditary peripheral nerve sheath tumours in a tertiary cancer institution in Singapore.
    Loh J; Ong PY; Goh DLM; Puhaindran ME; Vellayappan BA; Ow SGW; Chan G; Lee SC
    Hered Cancer Clin Pract; 2022 Jun; 20(1):23. PubMed ID: 35698239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound assessment of peripheral nerve pathology in neurofibromatosis type 1 and 2.
    Winter N; Rattay TW; Axer H; Schäffer E; Décard BF; Gugel I; Schuhmann M; Grimm A
    Clin Neurophysiol; 2017 May; 128(5):702-706. PubMed ID: 28315612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing biologically targeted clinical trials for neurofibromatosis.
    Gutmann DH; Blakeley JO; Korf BR; Packer RJ
    Expert Opin Investig Drugs; 2013 Apr; 22(4):443-62. PubMed ID: 23425047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of peripheral nerve sheath tumors: 17 years of experience at Toronto Western Hospital.
    Guha D; Davidson B; Nadi M; Alotaibi NM; Fehlings MG; Gentili F; Valiante TA; Tator CH; Tymianski M; Guha A; Zadeh G
    J Neurosurg; 2018 Apr; 128(4):1226-1234. PubMed ID: 28686119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
    Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
    Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and molecular characterization of neurofibromatosis in southern Brazil.
    Rosset C; Vairo F; Cristina Bandeira I; Fonini M; Netto CBO; Ashton-Prolla P
    Expert Rev Mol Diagn; 2018 Jun; 18(6):577-586. PubMed ID: 29685074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying challenges in neurofibromatosis: a modified Delphi procedure.
    Dhaenens BAE; Ferner RE; Bakker A; Nievo M; Evans DG; Wolkenstein P; Potratz C; Plotkin SR; Heimann G; Legius E; Oostenbrink R
    Eur J Hum Genet; 2021 Nov; 29(11):1625-1633. PubMed ID: 33903738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse models of neurofibromatosis 1 and 2.
    Gutmann DH; Giovannini M
    Neoplasia; 2002; 4(4):279-90. PubMed ID: 12082543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM
    Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofibromatosis. Nosological considerations.
    Badiu C; Stefanache F
    Rev Med Chir Soc Med Nat Iasi; 2000; 104(2):39-44. PubMed ID: 12089989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2).
    Shen YC; Arellano-Garcia C; Menjivar RE; Jewett EM; Dohle W; Karchugina S; Chernoff J; Potter BVL; Barald KF
    BMC Pharmacol Toxicol; 2019 Nov; 20(1):67. PubMed ID: 31730023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
    Hanemann CO; Blakeley JO; Nunes FP; Robertson K; Stemmer-Rachamimov A; Mautner V; Kurtz A; Ferguson M; Widemann BC; Evans DG; Ferner R; Carroll SL; Korf B; Wolkenstein P; Knight P; Plotkin SR;
    Neurology; 2016 Aug; 87(7 Suppl 1):S40-8. PubMed ID: 27527649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
    Banerjee J; Friedman JM; Klesse LJ; Yohay KH; Jordan JT; Plotkin SR; Allaway RJ; Blakeley JO
    Genet Med; 2023 Feb; 25(2):100324. PubMed ID: 36565307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neurofibromatosis versus schwannomatosis].
    Mautner VF; Schröder S; Pulst SM; Ostertag H; Kluwe L
    Fortschr Neurol Psychiatr; 1998 Jun; 66(6):271-7. PubMed ID: 9676422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS Tumors in Neurofibromatosis.
    Campian J; Gutmann DH
    J Clin Oncol; 2017 Jul; 35(21):2378-2385. PubMed ID: 28640700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.